Philogen provides update on pre-planned interim analysis of the Phase III FIBROSARC trial investigating Onfekafusp alfa (L19TNF) in patients with first-line advanced or metastatic Soft Tissue Sarcoma
FIBROSARC (NCT04650984) is a Phase III trial evaluating Onfekafusp alfa (L19TNF, also known as Fibromun) plus doxorubicin versus doxorubicin alone as front-line therapy for patients with advanced or metastatic Soft...
Read morePhilogen announces new publication in Nature Chemistry
The study was conducted by scientists at Philochem AG, the wholly owned Swiss subsidiary company of the Philogen group. The paper can be accessed on the Nature Chemistry website at...
Read morePhilochem will be attending the 10th World ADC Conference in London
Philochem will be attending the 10th World ADC Conference in London (United Kingdom) from March 2 to 5, 2020 10th World ADC London Dr. Samuele Cazzamalli will give a plenary lecture on: “Small...
Read morePhilogen announces publication in Chem (Cell Press) on novel affinity matured OncoFAP ligands
Philogen announces publication in Chem (Cell Press) on novel affinity matured OncoFAP ligands isolated from DNA-Encoded Chemical Libraries. The novel OncoFAP ligands show a prolonged residence time in Fibroblast Activation Protein (FAP)...
Read more